The soluble triggering receptor expressed on myeloid cells (sTREM)-1 has emerged as a potentially useful biomarker for the diagnosis of sepsis. This study aimed to evaluate the prognostic utility of serum sTREM-1 in septic shock, in comparison with that of procalcitonin measurements. Thirty-one consecutive patients in a tertiary medical intensive care unit with septic shock were studied. sTREM-1 levels in blood were measured using a modified immunoblot array technique on days one to three of intensive care unit admission. Serum procalcitonin and interleukin (IL)-1ß, IL-6, IL-10 and tumour necrosis factor-α levels were also measured. No significant difference was observed in the sTREM-1 levels on the first three days between survivors and nonsurvivors. sTREM-1 levels moderately correlated with the Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores on day three, but did not correlate with vasopressor requirements, cytokine levels and the presence of bacteraemia. In contrast, procalcitonin levels were significantly higher in nonsurvivors than in survivors on days two and three. A significant relationship also existed between procalcitonin levels and the other variables. In conclusion, this study found that the prognostic utility of serum sTREM-1 in septic shock is poor and that procalcitonin measurements perform better in this regard.
The triggering receptor expressed on myeloid cells (TREM)-1 is a member of the immunoglobulin (Ig) superfamily 1, 2 . Plasma levels of the soluble counterpart of TREM-1, sTREM-1, are increased in sepsis compared to patients without infection 3 . Aside from its diagnostic utility, several studies suggest that serum and plasma sTREM-1 may serve as a prognostic biomarker for sepsis [4] [5] [6] . Interestingly however, while some have found lower baseline sTREM-1 levels 4 , others have found higher baseline levels in nonsurvivors [5] [6] [7] . To complicate matters, another study suggests that sTREM-1 measurements provide no prognostic information in pneumonia 8 .
Considering the difficulties in interpreting the current literature on sTREM-1, we performed a prospective observational study on patients with septic shock, to determine whether serial measurements of serum sTREM-1 differed significantly between survivors and nonsurvivors, and to compare the prognostic utility of sTREM-1 with procalcitonin measurements, since the latter has recently emerged as a key biomarker in the management of sepsis 9 . We also evaluated the relationship between sTREM-1 levels and other surrogate markers of prognosis, including clinical severity scores, vasopressor requirements, cytokine levels and the presence of bacteraemia.
MATERIALS AND METHODS

Study population
Between January and April 2005, 31 consecutive adult patients with the diagnosis of septic shock were enrolled within 24 hours of admission to the Singapore National University Hospital's medical intensive care unit (ICU). We defined septic sTREM-1 and pRognosis in sEpTic shock shock according to the 2001 International Sepsis Definitions Conference 10 , i.e. sepsis with hypotension despite adequate volume resuscitation. Patients with acute coronary syndromes and acute cardiogenic pulmonary oedema, and patients for whom early withdrawal of intensive life support was considered were excluded. The study was approved by our Institutional Review Board and either the patients or their next of kin provided informed consent. These patients were also involved in another larger study of 72 patients which evaluated lactate, procalcitonin and amino-terminal B-type natriuretic peptide, but not sTREM-1 levels, in septic shock 11 . Sixty-two healthy blood donors to the local blood bank served as anonymous controls.
Serum sTREM-1 measurements
sTREM-1 levels in blood were measured using the modified immunoblot array technique reported previously 12 . Serum harvested from peripheral arterial blood within two hours of withdrawal was treated with pre-cooled ethanol for two hours in -20°C and the precipitated proteins were separated by centrifugation and re-dissolved with an equal volume of double strength sodium dodecyl sulphate sample buffer. One-microlitre aliquots of the patient samples were spotted, in triplicates, with sTREM-1 standards (human TREM-1/Fc Chimera protein 1278-TR, ranging from 0.05 to 1.0 ng/l) onto a nitrocellulose membrane. The membrane was probed with anti-sTREM-1 monoclonal antibody (IBQ02, R&D System, 1:500) for minimally two hours after blocking one hour with 5% BSA in Tris base-buffered saline-0.1% Tween20 (TBS-T). HRP-conjugated goat anti-mouse IgG (secondary) antibody (Molecular Probes, 1:5000) was applied for one hour and chemiluminescent signals were developed using SuperSignal ® West Pico Chemiluminescent Substrate (Pierce) and detected by the MULTI GENIUS Bio Imaging System. Spot intensity was analysed using GeneTools software (Syngene). Serum sTREM-1 levels in patient samples were extrapolated from the calibration curve generated from the concurrently-run sTREM-1 standards. The analytical sensitivity, reproducibility and linearity of the assay had been clinically validated 12 .
Other data collection
The patients' age, gender, diagnoses, microbiological culture results, Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores and vasopressor requirements on the first three days of ICU admission were recorded. Serum procalcitonin (LumiTest; Brahms Diagnostica, Berlin, Germany) and interleukin (IL)-1ß, IL-6, IL-10 and tumour necrosis factor (TNF)-α levels (IMMULITE; Diagnostics Products Corporation, Los Angeles, CA, USA) were measured simultaneously with sTREM-1 levels for the first three postadmission days. The primary outcome measure was 28-day all-cause mortality.
Clinical management
The investigators did not interfere with the attending physicians' clinical management, which was in accordance with the Surviving Sepsis Campaign guidelines 13 , i.e. aggressive fluid resuscitation in preload responsive patients, targeted vasopressor use, hydrocortisone for shock, initial broad spectrum antibiotics with subsequent de-escalation, lung protective ventilation, tight glucose control and deep vein thrombosis and stress ulcer prophylaxis.
Statistical analysis
The SPSS statistical software package 11.5 (SPSS Inc., Chicago, IL, USA) was used for data analysis. Nominal variables were expressed as frequencies, parametric variables as means ± standard deviation (SD) and nonparametric variables as medians with range. Univariate analyses were performed using the chi-square test or Fisher's exact test for nominal variables, the t-test for means and the Mann-Whitney U-test for medians. Spearman's rho (r s ) was used to evaluate the correlation between non-parametric variables. A receiver operating characteristics curve was constructed to determine various cut-off values of sTREM-1 and procalcitonin, with respect to mortality. A P value <0.05 was considered significant. All tests were two-tailed.
RESULTS
The characteristics of the 31 patients enrolled are shown in Table 1 . Six patients had gram-positive infections, 14 had gram-negative infections, one had both gram-positive and -negative infections and 10 had no micro-organisms detected. Sixteen patients (51.6%) were bacteraemic. The lungs were the primary source of sepsis in 18 patients, the genitourinary tract in seven, the gastrointestinal tract in five and the skin in one patient. The 28-day mortality rate was 35.5%. sTREM-1 levels were significantly higher in these patients with septic shock than the healthy blood donors (755.2 ng/ml [80.0 to 2746.6 ng/ml] vs. 83.1 ng/ml [30.0 to 249.5 ng/ml], P <0.001).
There was no difference in the sTREM-1 levels on the first three days between survivors and nonsurvivors ( Figure 1 ) -correspondingly, receiver operating characteristics curves (not displayed) showed that sTREM-1 measurements were not predictive of mortality. On the other hand, procalcitonin levels were significantly higher in nonsurvivors than in survivors on days two and three ( Figure 1 ). The area under the receiver operating characteristics curve (not displayed) when day two procalcitonin levels were used to predict mortality was 0.80 (95% confidence interval 0.59 to 1.00, P=0.009). At a cut-off of 185 ng/ml, procalcitonin measurements yielded a sensitivity of 70%, specificity of 90%, positive predictive value of 78%, negative predictive value of 86% and an accuracy of 83% for differentiating nonsurvivors from survivors.
There was no correlation between sTREM-1 levels and the APACHE II and SOFA scores till day three (Table 2 ). On the other hand, there was a stronger correlation between procalcitonin levels and these scores on both days two and three. Likewise, while there was no relationship between sTREM-1 levels and the severity of shock as reflected by vasopressor requirements and cytokine levels, there was a significant correlation between procalcitonin levels and these variables ( Table 2 ). There was also no association between sTREM-1 levels and the presence of bacteraemia, but procalcitonin levels were significantly higher in bacteraemic versus non-bacteraemic patients (88.9 ng/ml [4.9 to 608.2 ng/ml] vs. 31.8 ng/ml [1.7 to 267.5 ng/ml], P=0.006). Lastly, there was no correlation between sTREM-1 and procalcitonin levels on all three days (data not shown).
DISCUSSION
This study found that serial sTREM-1 measurements on days one to three were nonpredictive of 28-day mortality from septic shock, and that no relationship existed between sTREM-1 levels and vasopressor requirements, cytokine levels and bacteraemia. There was also no correlation between sTREM-1 levels and the APACHE II and SOFA scores until day three.
It is known that TREM-1 triggers and amplifies the inflammatory response in sepsis. Gibot and colleagues found lower baseline sTREM-1 levels in nonsurvivors than in survivors of sepsis 4 , and hypothesised that the release of sTREM-1 from monocytes prevents the engagement of membrane TREM-1, with sTREM-1 acting as a decoy receptor and hence an anti-inflammatory mediator 14 .
Time (days) However, three other studies found higher baseline sTREM-1 levels in nonsurvivors than survivors [5] [6] [7] . Yet another study found no relationship between sTREM-1 levels and outcomes in 302 patients with pneumonia, including severe pneumonia 8 . Our study now adds further doubt on the utility of sTREM-1 levels as a prognostic indicator in sepsis management. Animal models aside 15 , to the best of our knowledge, only two previous studies have attempted to demonstrate the correlation between sTREM-1 and cytokine levels in human sepsis -with conflicting results 6, 7 . The first study found a very weak correlation between levels of sTREM-1 and IL-10 6 , which was not seen in the second study 7 . The second study found correlations between sTREM-1 levels and IL-6 and IL-1 receptor antagonist levels, though the strengths of the correlations were not reported 7 . Our study, however, found no correlation between sTREM-1 levels and any cytokine.
The limitations of our study must be acknowledged. The small sample size increases the chance of a type II error, i.e. failure to find a significant relationship between sTREM-1 levels and mortality and the other variables which may truly exist. Besides, we limited our subjects to those with septic shock and not all patients with sepsis, thus making it more difficult to demonstrate the prognostic utility of sTREM-1 measurements, given the narrow spectrum of disease severity evaluated.
These limitations notwithstanding, within the same study population we found a significant relationship between procalcitonin measurements and these very same variables. Our demonstration of the prognostic utility of procalcitonin measurements is in keeping with the findings of prior studies 4,16-19 , including the above-mentioned study by Gibot and colleagues, where procalcitonin levels were more discriminative for mortality than sTREM1-1 levels 4 . The fact that procalcitonin measurements on days two and three had superior prognostic utility to those on day one suggests that trends matter more than absolute baseline levels for prognostication 16, 17 . Our other finding, that there was no correlation between sTREM-1 and procalcitonin levels, is also consistent with those of other investigators 3, 4, 8 .
In conclusion, this study found that the prognostic utility of serum sTREM-1 in septic shock is poor and that procalcitonin measurements perform better in this regard. We propose that further large-scale studies should be performed to evaluate this issue. 
